CAR-TCR Summit on September 23-26, 2025 in Boston, United States

Hope is renewed for the cell therapy industry in 2025 fuelled by a 30% year on year increase in investment, notably in the cases of Arsenal Bio, Enara Bio and AvenCell. Landmark approvals for solid tumors from Adaptimmune and Iovance, along with significant clinical progress from Adicet Bio and Cartesian Therapeutics all signify huge strides forward for the industry. Don't sit back and watch. Join the 10th Anniversary of the CAR-TCR Summit to reflect on a decade of progress whilst engaging in solutions-driven discussions that will empower you to tackle cell therapy development challenges to help shape the future of the field.

Built in collaboration with industry veterans including AstraZeneca, Cabaletta Bio, Arsenal Bio, Bristol Myers Squibb, Kyverna Therapeutics, T-knife Therapeutics, and Umoja Biopharma, this meeting will equip you to overcome challenges across the entire development landscape - spanning durability, manufacturing timelines, potency assay matrix, solid tumor targeting, biomarker data, high cost of goods, scale up and scale out, and more, to make rapid advancements in the clinic and beyond. This is your definitive annual industry touchpoint to unlock breakthrough platform technology, accelerate clinical translation, and streamline manufacturing to deliver life changing cell therapies for patients in oncology and beyond.

Whether your focus is on Discovery, Translation, Clinical Development, Early-Stage Manufacturing, Late-Stage Manufacturing, or Analytical Development you can expect to gain in-depth insights across the entire cell therapy value chain.

Is industry collaboration your priority? Take part in 15+ hours of dedicated networking, from drinks receptions, poster sessions, and pharma partnering mixers. Maximize your opportunity to meet key industry stakeholders and expand your network.

URLs:

Website: https://go.evvnt.com/3003078-0?pid=10008

Tickets: https://go.evvnt.com/3003078-2?pid=10008

Brochure: https://go.evvnt.com/3003078-3?pid=10008

Prices:

4 Day Pass: Conference + (Workshop Day OR Fundamentals Day OR Partnering Day) + Post-Day - Drug Developer Pricing: USD 5495.00,

4 Day Pass: Conference + (Workshop Day OR Fundamentals Day OR Partnering Day) + Post-Day - Academic Pricing: USD 4695.00,

4 Day Pass: Conference + (Workshop Day OR Fundamentals Day OR Partnering Day) + Post-Day - Vendor Pricing: USD 7875.00,

3 Day Pass: Conference + Workshop Day OR Fundamentals Day OR Partnering Day OR Post-Day - Drug Developer Pricing: USD 4297.00,

3 Day Pass: Conference + Workshop Day OR Fundamentals Day OR Partnering Day OR Post-Day - Academic Pricing: USD 3697.00,

3 Day Pass: Conference + Workshop Day OR Fundamentals Day OR Partnering Day OR Post-Day - Vendor Pricing: USD 6577.00,

Conference Only - Drug Developer Pricing: USD 3099.00,

Conference Only - Academic Pricing: USD 2699.00,

Conference Only - Vendor Pricing: USD 5279.00

Speakers: Polly Brown, Vice President and Head of Business Development, Oncology, Research and Development, AstraZeneca, Deanna Mele, Senior Director, Business Development, Search and Evaluation, AstraZeneca, Gadi Bornstein, Senior Director, External Innovation, Discovery, Product Development and Supply, Johnson and Johnson, Hong Xin, Senior Director Search and Evaluation, Johnson and Johnson, Christopher Tan, Executive Director, Search and Evaluation Business Development and Licensing, Merck, Asthika Goonewardane, Managing Director, Equity Research Biotech, Truist Securities, Cecile Bauche, Chief Scientific Officer and Co-Founder, Alaya.bio, Preet Chaudhary, Director of Cell Therapy and BMT, University of Southern California, Founder, Angeles Therapeutics, Jason Damiano, Chief Scientific Officer, Appia Bio, Adrian Bot, Chief Scientific Officer,Capstan Therapeutics, Felix Lorenz, Chief Executive Officer/ Chief Scientific Officer, Captain T Cel, Deborah Rathjen, Chief Executive Officer, Carina Biotech, Ulrik Cordes, Chief Executive Officer, Cbio, David Sourdive, Co-founder, Executive Vice President CMC, Cellectis, Philippe Parone, Chief Scientific Officer, Esobiotech, Sareina Wu Founder, Chief Executive Officer, Chief Scientific Officer, GenomeFrontier, Birgit Schultes, Executive Vice President, Chief Scientific Officer, Intellia Therapeutics, Anna Truppel-Hartmann, Chief Medical Officer, KSQ Therapeutics, Micah Benson, Chief Scientific Officer, KSQ Therapeutics, Naji Gehchan, Chief Medical and Development Officer, Kyverna Therapeutics, Warner Biddle, Chief Executive Officer, Kyverna Therapeutics, Mythili Koneru, Chief Medical Officer, Legend Biotech, Jennifer Buell, President and Chief Executive Officer, MiNK Therapeutics, Robert Hofmeister, Chief Scientific Officer, Myeloid therapeutics, Maurits Geerlings, Chief Executive Officer, Nanocell Therapeutics, Nan Zhang, Chief, Cell Therapy Manufacturing Section, NIH, Raphael Ognar, Chief Executive Officer, NKILT Theapeutics, Stefanos Theoharis, Chief Executive Officer, Onechain Immunotherapeutics, Dora Hammerl, Vice President, Research and Development, CoFounder, Pan Cancer T, Daniel Shelly, Chief Business Officer, PolTREG, Ulf Grawunder, Chief Executive Officer, T-CURX, Peggy Sotirolpoulou, Chief Scientific Officer,T-knife Therapeutics, Ryan Crisman, Co-Founder and Chief Technology Officer, Umoja Biopharma, Mark Cobbold, Senior Vice President Immuno-Oncology, Discovery and Cell Therapy Oncology, AstraZeneca, Harita Babber, AS and T Director, Regulatory Affairs, CMC, Quality Control Tech Lead, BioNTech, Marcella Goodnight, Senior Director, MS and T, BioNTech, Alexis Melton, Director, Early Clinical Development Hematology and Cell Therapy, Bristol Myers Squibb, Bassem Gayed, Senior Director, Technical Process Engineering, CAR-T MS and T, Bristol Myers Squibb, Stephan Krause, Executive Director, Analytical Quality, Cell Therapies, Bristol Myers Squibb, Sapna Chhagan, Executive Director, Clinical Sciences, Cell Therapy, Early Clinical Development, Bristol Myers Squibb, Vaishali Shukla, Vice President CGT and API Global Expansion, Eli Lilly, Niraj Ramachandran, Senior Director, Technical Regulatory Cell and Gene Therapies, Genentech, Manoj Chiney, Director, Clinical Pharmacology, Gilead Sciences, Vicki Plaks, Senior Director, Head of Oncology Translational Research, Johnson and Johnson, Rocio Montes de Oca, Scientific Director, Oncology Translational Research, Cell Therapy, Johnson and Johnson, Stella Khiew, Senior Scientist, Merck, Peter Gergely Global Head of Immunology, Translational Medicine, Novartis, Yan Wang, Director, Head of Cellular Process Development, Regeneron, Nelly Viseaux, Vice President, Cell Therapies Development, Manufacturing Supply and Quality, Regeneron, Masoud Golshadi, Senior Scientist, Takeda, Yana Wang, Senior Director, Cell Therapy Oncology, Takeda, Breanna DiAndreth, Principal Scientist, A2 Biotherapeutics, Michael McLaughlin, Senior Scientist, Abeona Therapeutics, Shon Green, Vice President, Non Clinical Development, Adicet Bio, Simona Costanzo, Vice President, Program Leadership and Management, Adicet Bio, Patrick Halvey, Director, Clinical Biomarker Development, Affini-T Therapeutics, Tamar Thompson, Head Corporate Affairs, Alexion Pharmaceuticals, Tuhin Bhowmik, Associate Director, Process Engineering and MST, Arcellx, Stephen Santoro, Product Team Lead, Arsenal Bio, Haixia Wang, Director, Analytical Development, Arsenal Bio, Aaron Cooper, Vice President, Early Discovery, Arsenal Bio, Jason Awe, Head, Corporate Communications and IR, Atara Bio, Matthew Li, Senior Director, Aurion Biotech, Tishwant Kanwarjit, Executive Director, Head of Quality, Autolus, Ketki Vispute, Assocaite Director Cell Manufacturing and CMC, Autolus, Gerardo Toledo, Director, Cell Process Development, Autolus, Rich Getto, Senior Vice President, Product Operations, BrainChild Bio, Gwen Binder, President, Science and Technology, Cabaletta Bio, Yan Li, Director, Process Development, Cabaletta Bio, John Rossi, Vice President, Head of Translational Medicine, Capstan Therapeutics, Enrique Zudaire, Senior Vice President of Translational Sciences and Therapeutics Discovery, Caribou Biosciences, Justin Skoble, Vice President, Technical Operations, Caribou Biosciences, Thomas Condamine, Vice President, Discovery and Translational Sciences, Carisma Therapeutics, Bryan Zimdahl, Senior Director, Clinical Science and Regulatory Affairs, Eureka Therapeutics, Zhiyuan Yang, Director, Analytics, Eureka Therapeutics, Ian Gaudet, Head of US Technical Operations, Galapagos, Howard Cheng, Director, Clinical Development, GenomeFrontier, Poonam Sharma, Associate Director, Process Development, GentiBio, Ruth Berry, Senior Director, Analytical Strategy, GentiBio, Mamta Kalra, Vice President, Process and Analytical Development, Immatics, Nina Moeker, Vice President, Development Lead Preclinical Portfolio, Immatics, Brent Chesson, Associate Director, Process Development, Immatics, Ben Oshrine, Senior Medical Director, Early Clinical Development, Legend Biotech, Shobha Potluri, Vice President, Translational Sciences and Bioinformatics, Lyell Immunopharma, Melissa DeFrancesco, Director, Process Development, Lyell Immunopharma, Jodie Wehling, Vice President Market Access, Mesoblast, Kingyin Lee, Head of Clinical Trials, MHRA, Theodore Giaviridis, Head of Preclinical Research and Development, OverT Bio, Brian Garrison, Vice President, Research, Sentio Bio, Therese Choquette, Head of Analytical and Translational Sciences, Tigen Pharma, Cagan Gurer, Senior Vice President, Discovery and Preclinical Development, Tscan Therapeutics, Elisaveta Todorova, Associate Director, Process Development and Technology Innovation, Tscan Therapeutics, Raymond Luke, Senior Director MS and T and Head of CMC, Verismo Therapeutics, Lavanya Peddada, Senior Director, Process Development, Vittoria Biotherapeutics, Junxia Wang, Executive Member Women in Bio; The Association for Women in Science, Marcela Maus, Director Cellular Immunotherapy, Program Paula O'Keefe Endowed Chair, Massachussets General Hospital Cancer Center, Xiuyan Wang, Director, Cell Therapy Engineering, Memorial Sloan Kettering Cancer Center, Steven Feldman, Director and Head of Site Scientific, Stanford University, Krishna Komanduri, Professor and Chief, Division of Hematology and Oncology, UCSF Health, David Porter, Exectuvie Director, Center for Cell Therapy and Transplant, University of Pennsylvania

Category: Conferences | Science, Health and Medicine

Date and Time: 23rd September 2025 at 8:00 am to 26th September 2025 at 5:00 pm